Platelet-activating factor modulates gastric mucosal inflammatory responses to Helicobacter pylori lipopolysaccharide

Biochemical and Biophysical Research Communications

Volumn 306, Issue 1, 2003, Pages 261-266

  Slomiany, Bronislaw L ^a   Slomiany, Amalia ^a  

^a UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

Author keywords

Acute gastritis; COX 2; Helicobacter pylori LPS; NOS 2; PAF; TNF

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; GINKGOLIDE A; ISOENZYME; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; N [3 (AMINOMETHYL)BENZYL]ACETAMIDINE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE INHIBITOR; PROSTAGLANDIN; THROMBOCYTE ACTIVATING FACTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG POTENTIATION; EXPERIMENTAL MODEL; GASTRITIS; HELICOBACTER PYLORI; INFECTION PREVENTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; STOMACH MUCOSA; STOMACH PROTECTION; UPREGULATION;

ANIMALIA; HELICOBACTER; HELICOBACTER PYLORI;

EID: 0038730715     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-291X(03)00944-6     Document Type: Article

References (24)

1. Tytgat G.N.J. Current indications for Helicobacter pylori eradication therapy. Scand. J. Gastroenterol. 31(Suppl. 215):1996;70-75.
2. de Boer W.A. Topics in Helicobacter pylori infection: focus on a 'search-and-treat' strategy for ulcer disease. Scand. J. Gastroenterol. 35(Suppl. 232):2000;4-9.
3. Piotrowski J., Piotrowski E., Skrodzka D., Slomiany A., Slomiany B.L. Induction of acute gastritis and epithelial apoptosis by Helicobacter pylori lipopolysaccharide. Scand. J. Gastroenterol. 32:1997;203-211.
4. Brzozowski T., Konturek P.C., Sliwowski Z., Drozdowicz D., Pajdo R., Stachura J., Hahn E.G., Konturek S.J. Lipopolysaccharide of Helicobacter pylori protects gastric mucosa via generation of nitric oxide. J. Physiol. Pharmacol. 48:1997;699-717.
5. Fu S., Ramanujam K.S., Wong A., Fantry G.T., Drachenberg C.B., James S.P., Meltzer S.J., Wilson K.T. Increased expression and cellular localization of inducible nitric oxide synthase and cyclooxygenase 2 in Helicobacter pylori gastritis. Gastroenterology. 116:1999;1319-1329.
6. Slomiany B.L., Slomiany A. Blockade of p38 mitogen-activated protein kinase pathway inhibits inducible nitric oxide synthase and gastric mucosal inflammatory reaction to Helicobacter pylori lipopolysaccharide. Inflammopharmacology. 8:2001;371-382.
7. Slomiany B.L., Slomiany A. Suppression of gastric mucosal inflammatory responses to Helicobacter pylori lipopolysaccharide by peroxisome proliferator-activated receptor γ activation. IUBMB Life. 53:2002;303-308.
8. Brinkman B.M.N., Telliez J.B., Schievella A.R., Lin L.L., Goldfeldt A.E. Engagement of tumor necrosis factor (TNF) receptor 1 leads to TAF-2- and p38 mitogen-activated protein kinase-dependent TNF-α gene expression. J. Biol. Chem. 274:1999;30882-30886.
9. Poligone B., Baldwin A.S. Positive and negative regulation of NF-κB by COX-2. J. Biol. Chem. 276:2001;38658-38664.
10. Wilson K.T., Fu S., Ramanujam K.S., Meltzer S.J. Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's esophagus and associated adenocarcinomas. Cancer Res. 58:1998;2929-2934.
11. Gupta R.A., Polk D.B., Krishna U., Israel D.A., Yan F., BuBois R.N., Peek R.M. Activation of peroxisome proliferator-activated receptor γ suppresses nuclear factor κB-mediated apoptosis induced by Helicobacter pylori in gastric epithelial cells. J. Biol. Chem. 276:2001;31059-31066.
12. Marnett L.J., Wright T.L., Crews B.C., Tannenbaum S.R., Morrow J.D. Regulation of prostaglandin biosynthesis by nitric oxide is revealed by target deletion of inducible nitric-oxide synthase. J. Biol. Chem. 275:2000;13427-13430.
13. 2 synthesis and cyclooxygenase-2 activity are regulated both by a nitric oxide-dependent and -independent mechanism in rat osteoblasts in vitro. J Biol. Chem. 274:1999;1776-1782.
14. Choi J.H., Ko H.M., Kim J.W., Lee H.K., Han S.S., Chun S.B., Im S.Y. Platelet-activating factor-induced early activation of NF-κB plays a crucial role for organ clearance of Candida albicans. J. Immunol. 166:2001;5139-5144.
15. Han S.J., Ko H.M., Choi J.H., Seo K.H., Lee H.S., Choi E.K., Choi I.W., Lee H.K., Im S.Y. Molecular mechanisms for lipopolysaccharide-induced biphasic activation of NF-κB. J. Biol. Chem. 277:2002;44715-44721.
16. Karin M., Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-κB activity. Ann. Rev. Immunol. 18:2000;621-663.
17. Lawrence T., Gilroy D.W., Colville-Nash P.R., Willoughby A. Possible new role for NF-κB in the resolution of inflammation. Nature Med. 7:2001;1291-1297.
18. Wallace J.L., Ma L. Inflammatory mediators in gastrointestinal defense and injury. Exp. Biol. Med. 226:2001;1003-1015.
19. Vincent J.L., Spapen H., Bakker J., Webster N.R., Curtis L. Phase II multicenter clinical study of the platelet-activating factor receptor antagonist BB-882 in the treatment of sepsis. Crit. Care Med. 28:2000;638-642.
20. Han S.J., Choi J.H., Ko H.M., Yang H.W., Choi I.W., Lee H.K., Lee O.H., Im S.Y. Glucocorticoids prevent NF-κB activation by inhibiting the early release of platelet-activating factor in response to lipopolysaccharide. Eur. J. Immunol. 29:1999;1334-1341.
21. Gilroy D.W., Colville-Nash P.R., Willis D., Chivers J., Paul-Clark M.J., Willoughby D.A. Inducible cyclo-oxygenases may have anti-inflammatory properties. Nature Med. 5:1999;698-701.
22. Hortelano S., Castrillo A., Alvarez A.M., Bosca L. Contribution of cyclopentanone prostaglandins to the resolution of inflammation through the potentiation of apoptosis in activated macrophages. J. Immunol. 165:2000;6525-6531.
23. 2. Proc. Natl. Acad. Sci. USA. 96:1999;4668-4673.
24. Slomiany B.L., Piotrowski J., Slomiany A. Induction of caspase-3 and nitric oxide synthase-2 during gastric mucosal inflammatory reaction to H. pylori lipopolysaccharide. Biochem. Mol. Biol. Int. 46:1998;1063-1070.